Therapeutic applications of AS1411 aptamer, an update review
Abstract
Nucleolin or C23, is one of the most abundant non-ribosomal phosphoproteins of nucleolus. However, in several cancers, nucleolin is highly expressed both intracellularly and on the cell surface. So, it is considered as a potential target for the diagnosis and cancer therapy. Targeting nucleolin by compounds such as AS1411 aptamer can reduce tumor cell growth. In this regard, interest has increased in nucleolin as a molecular target for overcoming cancer therapy challenges. This review paper addressed recent progresses in nucleolin targeting by the G-rich AS1411 aptamer in the field of cancer therapy mainly over the past three years.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
AS1411 aptamer specifically binds to nucleolin, which is highly expressed on nucleus and tumor cell membranes.
“AS1411 aptamer is a 26-molecule DNA oligonucleotide accidentally discovered by Bates et al.253 It can specifically bind to nucleolin, which is highly expressed on the nucleus and on the surface of tumor cell membranes.254”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [254]
The citation lists haven’t been fetched yet
References 133 · Cited by 288
- Authors
- Yazdian-Robati, R., Bayat, P., Oroojalian, F., Zargari, M., Ramezani, M., Taghdisi, S. M., & Abnous, K.
- Affiliations
- Mashhad University of Medical Sciences (IR)
- North Khorasan University of Medical Sciences (IR)
- Mazandaran University of Medical Sciences (IR)
- Corresponding author
- Taghdisi, Seyed Mohammad
- Abnous, Khalil
- Venue
- International Journal of Biological Macromolecules
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 155
- Pages
- 1420-1431
- ISSN
- 0141-8130 (ISSN-L)
- OpenAlex
- W2986752244
- Semantic Scholar
- 5c29a0c5cee09b6053a6c47dbe9f74d13fc9b8c6
- Cited by
- 288
- References
- 133
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 45 · 2023: 62 · 2022: 49 · 2021: 46 · 2020: 20
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Biological Macromolecules (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mazandaran University of Medical Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- AS1411 aptamer, nucleolin, C23, nucleolus, tumor cell growth inhibition, cancer diagnosis
- MeSH terms
- Nucleolin, Humans, Neoplasms, Oligodeoxyribonucleotides, Phosphoproteins, RNA-Binding Proteins, Aptamers, Nucleotide, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
